NEW APPROACH TO THE OXYBUPROCAINE IDENTIFICATION IN THE DRUGS

Authors

  • M. G. Levin State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”
  • V. N. Britsun State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”
  • N. L. Tarasenko State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”
  • N. A. Savina State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”
  • N. V. Оstanina State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

DOI:

https://doi.org/10.11603/2312-0967.2018.1.8619

Keywords:

oxybuprocaine, carbon disulfide, n-hexan, IR-spectroscopy, identification.

Abstract

The aim of the work. Development of an improved, carbon disulfide free method for the determination of oxybuprocaine in pharmaceuticals.

Materials and Methods. Identification of the active pharmaceutical ingredient of  oxybuprocaine dosage forms by IR spectroscopy in KBr tablets after extraction with volatile organic solvent.

Results and Discussion. Instead of carbon disulphide, a less fire-hazardous and less toxic n-hexane was used to extract the base of oxybuprocaine. After evaporation of the solvent, the infrared spectra of the standard sample and the test substance (test sample) were recorded under the same conditions. Comparison of IR spectra indicates a coincidence of  95 %, which confirms the legitimacy of the replacement of carbon disulfide by n-hexane.

Conclusion. The developed approach has advantages over the known technique with the absence of fire-hazardous and poisonous carbon bisulphide.

Author Biographies

M. G. Levin, State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

lead researcher, doctor of chemical sciences, State scientific research laboratory for quality  control of  medicines, State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

V. N. Britsun, State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

chief researcher, doctor of chemical sciences, State scientific research laboratory for quality  control of  medicines, State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

N. L. Tarasenko, State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

lead engineer, State scientific research laboratory for quality  control of  medicines, State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

N. A. Savina, State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

lead engineer, State scientific research laboratory for quality  control of  medicines, State Institution “O.M. Marzeyev Institute for Public Health of the National academy of medical sciences of Ukraine”

N. V. Оstanina, State Institution “O.M. Marzeyev Institute for public health of the National academy of medical sciences of Ukraine”

candidate of economic sciences, scientific researcher, head of the State scientific research laboratory for quality  control of  medicines, State Institution “O.M. Marzeyev Institute for Public Health of the National academy of medical sciences of Ukraine”

References

State Pharmacopoeia of Ukraine: in 3 vol. State Enterprise "Ukrainian Research Center expert pharmacopoeia quality medicines" – 2nd ed. Kharkiv: 2015. Ukrainian.

Lazarev NV, Gadaskina YD.Vrednyye veshchestva v promyshlennosti: in 3 tomakh. Tom 3. [Вредные вещества в промышленности: в 3-х т. Т.3] Leningrad: Khimiya; 1977. Russian.

Douet JY, Michel J, Regnier A. Degree and duration of corneal anesthesia after topical application of 0.4% oxybuprocaine hydrochloride. Am J Vet Res. 2013 74(10): 1321-6.

DrugBank Version 4.5 [Electronic resource]. – Available from: http://www.drugbank.ca/drugs/DB00892

Haddad R. Fibrinous iritis due to oxybuprocaine. Brit J Ophthalmol. 1989(73): 76-7.

Downloads

Published

2018-03-24

How to Cite

Levin, M. G., Britsun, V. N., Tarasenko, N. L., Savina, N. A., & Оstanina N. V. (2018). NEW APPROACH TO THE OXYBUPROCAINE IDENTIFICATION IN THE DRUGS. Pharmaceutical Review Farmacevtičnij časopis, (1), 63–65. https://doi.org/10.11603/2312-0967.2018.1.8619

Issue

No. 1 (2018)

Section

Analysis of drugs

License

The authors who publish their materials in this journal agree with the following terms:

  • Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal Результат пошуку зображень за запитом "CC-BY logo".
  • Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.

Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).